Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology (ICO), shared on X:
“STAR-01 at ESMOGI25: tumor immune microenvironment (TIME) and survival in LARC after pre-op CRT
303 pts | 110 paired samples
- High post-CRT CD20+, TILs and low CD4/CD8 → improved EFS and OS
- CD20+ cells ≥1% pre-CRT trended with better 5y-EFS (HR 0.59; p=0.051)
TIME may not just tell the story – it could write the prognosis.”
More posts featuring ESMOGI25.
